Eczema (Atopic Dermatitis): Triggers, Daily Skin Care and Updated Treatments

Evidence reviewed: 8 November 2026. Eczema, particularly atopic dermatitis (AD), causes chronic or recurring itchy skin inflammation and can affect children and adults. It is associated with skin-barrier dysfunction and immune inflammation, often alongside environmental irritants. The most useful starting point is regular moisturizing and appropriately selected anti-inflammatory treatment, not indiscriminate food avoidance or routine antibiotics. The American Academy of Dermatology (AAD) updated its treatment guidelines in 2025 to include newer topical and biologic therapies [1–3].

How does atopic dermatitis develop?

Healthy skin limits water loss and protects against irritants and microbes. In atopic dermatitis, skin barrier defects and inflammatory signaling—particularly pathways involving IL-4 and IL-13—can promote dryness, inflammation and itching. Genetic variations such as changes affecting filaggrin contribute in some patients, but not everyone with eczema has a detectable mutation [1].

Scratching worsens barrier injury and inflammation, creating an itch–scratch cycle. Eczema is not contagious and does not necessarily mean that a person has a food allergy. Family or personal histories of asthma or allergic rhinitis are common but not required for diagnosis.

What does eczema look like?

Common features include itching, dryness, rough patches, scaling, inflammation, cracks and sometimes oozing or crusting. Infants may have facial and extensor-surface disease, whereas older children and adults often have changes in elbow or knee creases, hands, neck, eyelids or other areas. Longstanding scratching can cause lichenification, a thickened skin texture [1].

On darker skin, inflammation may look purple, brown, gray or skin-colored rather than bright red, and pigment changes can persist after active eczema improves. Eczema may coexist with contact dermatitis, fungal infection or psoriasis, so atypical or treatment-resistant eruptions warrant reassessment.

Common eczema triggers and irritants

Possible aggravating factor Practical adjustment
Fragranced soaps and detergents Choose gentle, fragrance-free products; avoid frequent scrubbing.
Dry air, heat or sweating Adjust clothing and temperature for comfort; moisturize regularly.
Rough fabrics and friction Use comfortable clothing and reduce repeated rubbing.
Repeated wet work or cleaning products Protect hands from irritants and moisturize after washing.
Allergic contact dermatitis Consider patch testing when a relevant contact allergen is suspected.
Infection or skin injury Seek assessment for significant spreading inflammation or suspected bacterial/viral infection.

Stress and sleep disturbance may worsen the itch–scratch cycle, but eczema should not be described as a psychological condition. Do not impose a long list of unverified triggers; focus on exposures that consistently aggravate the person’s symptoms [2,3].

A simple morning and evening eczema routine

Morning

  1. Use lukewarm water and a gentle fragrance-free cleanser only as needed.
  2. Pat skin dry rather than rubbing.
  3. Apply a thick moisturizer promptly, including after handwashing when possible.
  4. Apply any prescribed anti-inflammatory treatment to affected areas as directed.
  5. Use appropriate sun protection on exposed skin, selecting a formulation that does not sting.

Evening

  1. Take a short warm—not hot—bath or shower if desired; avoid harsh scrubbing.
  2. Apply prescribed treatment to active eczema according to the care plan.
  3. Apply moisturizer generously to the rest of the skin and repeat on dry patches as needed.
  4. Keep nails reasonably short and consider non-irritating clothing to reduce injury from scratching during sleep.

Moisturizer is not merely cosmetic. The AAD strongly recommends moisturizers for adult AD; they help reduce water loss and can reduce the need for anti-inflammatory therapy in some patients [1]. Creams and ointments may be more suitable than thin scented lotions, though preference and tolerability matter.

Topical corticosteroids: effective when used correctly

Topical corticosteroids remain a cornerstone for controlling eczema flares. Potency, frequency, duration and site must be matched to the patient. Thin skin such as eyelids, face, groin and skin folds generally needs greater caution than thick skin on palms or soles. Correctly used corticosteroids are important and should not be withheld unnecessarily because of generalized fear, but prolonged unsupervised high-potency use can cause skin thinning and other adverse effects [1,2].

Patients should receive clear instructions about the amount and area of application. An individualized proactive maintenance approach, such as intermittent anti-inflammatory treatment to frequently recurring sites under clinician supervision, may prevent flares more effectively than repeatedly allowing severe inflammation to return [2].

Nonsteroidal topical treatments

Class Examples and purpose Important cautions
Calcineurin inhibitors Tacrolimus ointment and pimecrolimus cream may help sensitive areas and maintenance. Transient burning may occur; age and application instructions vary.
PDE4 inhibitors Crisaborole and roflumilast formulations for suitable patients and ages. Formulation, indication and local licensing matter.
Topical JAK inhibitors Ruxolitinib cream for appropriately selected patients in countries where approved. Specific area/duration restrictions and boxed safety warnings may apply.
Aryl hydrocarbon receptor agonist Tapinarof cream, added to updated AAD recommendations for adults. Potential irritation or folliculitis; product-specific age and indication.

The 2025 AAD focused update added strong evidence-based recommendations for tapinarof and roflumilast creams for appropriate adult AD populations and for newer systemic biologics [1]. This does not mean that all drugs are available or approved at all ages in every country. The right topical treatment depends on eczema severity, site, cost, pregnancy and previous response.

When eczema is moderate to severe

Persistent widespread disease, significant sleep disruption, recurrent infection or inadequate response to a correctly used topical plan may justify referral to dermatology. The AAD supports selected phototherapy, biologics and oral targeted treatments for moderate-to-severe AD when appropriate [1,3].

Treatment Clinical role
Dupilumab or tralokinumab Biologic therapies targeting type-2 inflammatory pathways, appropriate in selected patients.
Lebrikizumab IL-13-targeted biologic strongly recommended in the 2025 adult update for suitable moderate-to-severe AD.
Nemolizumab Targets IL-31 receptor signaling, a pathway linked to itch; recommended with concomitant topical treatment for suitable adults.
Upadacitinib or abrocitinib Oral JAK inhibitors that can be effective but require careful infection, thrombosis, malignancy, cardiovascular and laboratory risk assessment.
Narrowband UVB phototherapy An option in selected patients under specialist supervision.

Drug eligibility and indications vary by jurisdiction. Systemic corticosteroids are recommended against for routine AD treatment by the AAD because of adverse effects and the risk of rebound disease; they should not be described as a long-term maintenance solution [1]. Conventional immunosuppressants may have roles in particular settings, but need monitoring.

Should someone with eczema avoid milk, eggs or gluten?

Not routinely. A severe eczema flare does not establish that a food caused it. Indiscriminate elimination of dairy, eggs, wheat and other nutritious foods can cause malnutrition, weight loss or additional anxiety, especially in children. The AAAAI/ACAAI joint guideline recommends against routine elimination diets for AD in the absence of a confirmed relevant food allergy [2].

Seek specialist assessment if there are reproducible immediate reactions such as hives, wheezing or vomiting after a particular food. Testing should follow clinical history; a positive sensitization test by itself does not always mean that avoiding a food will improve eczema. Do not restrict major food groups for young children without qualified advice.

Are bleach baths, antibiotics or antiseptics needed?

Routine topical antibiotics and antiseptics are not recommended for uncomplicated eczema. The AAD guideline recommends against routine topical antimicrobial therapies [1]. Appropriate dilute bleach baths may be considered for selected patients with moderate-to-severe disease under clinician-directed instructions, particularly when infection-related factors are important; they are not a universal treatment for mild eczema [2].

Never improvise bleach concentrations or apply household cleaning products directly to the skin. Infection warrants proper assessment. Honey-colored crusts, pus, increasing warmth or spreading redness may suggest a bacterial infection. Painful clusters of blisters, fever and rapidly worsening eczema can indicate eczema herpeticum, a potentially serious viral condition requiring urgent antiviral evaluation.

Wet-wrap therapy and itch management

Wet-wrap therapy uses a damp layer and a dry covering over moisturized or appropriately treated skin, sometimes helping selected severe flares. It should be introduced with clinical advice, particularly when corticosteroids are used under occlusion because absorption may increase [1,2]. Sedating antihistamines do not routinely treat the underlying eczema inflammation and may cause adverse effects; the AAD does not recommend topical antihistamines for AD.

Sleep routines, minimizing heat, gentle clothing and suitable itch management can improve quality of life, but these are adjuncts to anti-inflammatory treatment.

When is patch testing appropriate?

Allergic contact dermatitis can coexist with atopic dermatitis. Consider patch testing when eczema worsens with particular products, affects the hands or face in a pattern suggesting exposure, or persists despite appropriately used treatment. Patch testing is not the same as skin-prick testing for immediate allergies and should be performed and interpreted by trained clinicians.

Frequently asked questions

Is eczema contagious?

No. Atopic dermatitis itself is not contagious, although an infected lesion may require infection-specific precautions.

Is moisturization enough for every eczema flare?

No. Regular moisturizer is foundational, but active inflammation frequently needs an appropriate topical anti-inflammatory medicine [1].

Should every child with eczema avoid eggs and milk?

No. Avoid blanket elimination diets unless a relevant allergy is properly identified [2].

Are oral steroids a recommended long-term eczema treatment?

No. The AAD recommends against routine systemic corticosteroids for atopic dermatitis [1].

What if a flare becomes painful, blistered and accompanied by fever?

Seek urgent care to exclude eczema herpeticum or another serious skin infection.

Key takeaways

Eczema management begins with gentle cleansing, regular moisturizer and appropriate anti-inflammatory treatment. Avoid unnecessary food restriction, antibiotics and prolonged systemic steroids. Severe disease may benefit from specialist biologic or targeted therapies under the 2025 AAD update.

References

  1. American Academy of Dermatology. Atopic dermatitis clinical practice guidelines, including 2025 focused update. Accessed 8 Nov 2026.
  2. Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 AAAAI/ACAAI Joint Task Force recommendations. Ann Allergy Asthma Immunol. 2024;132:274–312. Clinical summary.
  3. American Academy of Dermatology. Focused update: guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol. 2025;93:745.e1–745.e7. doi:10.1016/j.jaad.2025.05.1386.
  4. National Eczema Association. Eczema treatments. Accessed 8 Nov 2026.

Medical disclaimer: This article provides general education. Children, pregnant patients and people with extensive disease need individualized care. Seek urgent help for a rapidly painful blistering eruption, fever or serious infection signs. Prescription medicines require clinician guidance.

Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *